Ranbaxy got final approval for Aricept

Indian pharma major, Ranbaxy got the final approval from USFDA for marketing of Aricept generic version. Additionally Ranbaxy holds the 180 day exclusivity for this product which will allow them to sell the generic version in US market without any other generic competition. Therefore Ranbaxy expecting US $200 million from this 180 days selling of generic version of Aricept. Aricept is the brand name containing Donepezil as active ingredient and is used for Alzheimer's disease.